Scientists found that TAZ, a coactivator of TEAD transcription factors of Hippo signaling, was expressed under TH17 cell–inducing conditions and was required for TH17 differentiation and TH17 cell–mediated inflammatory diseases. [Nat Immunol]
Abstract

The authors report that selective deletion of gp96 from CD11c+ cells in mice results in alteration of dendritic cell and T cell subsets in the gut as well as loss of antigen-specific regulatory T cell induction in the mesenteric lymph nodes. [Sci Rep]
Full Article

Using CD4+ T cells from jlp-deficient and jlp-wild-type mice, investigators demonstrated that JLP-deficiency impaired T-cell proliferation, IL-2 production, and CD154 induction upon TCR stimulations, but had no impacts on the expression of other surface molecules such as CD25, CD69, and TCR. [Mol Immunol]
Abstract

The authors review the current knowledge of the development, activation and pathophysiological functions of γδ17 T cells, aiming to increase the awareness in the community of the therapeutic potential of this ‘other side’ of interleukin 17 (IL-17)-mediated immune responses. [Nat Immunol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the immune regulation research field.

Deciphera Pharmaceuticals announced that a poster presentation that includes updated results from the ongoing Phase I clinical study of DCC-2618, the company’s pan-KIT and PDGFR inhibitor, will be presented. [Press release from Deciphera Pharmaceuticals discussing research to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Press Release

Hutchison China MediTech Limited announces that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and sulfatinib, will be presented. [Press release from Hutchison China MediTech Limited discussing research to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Press Release

NOXXON Pharma N.V. announced the signing of an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg under which the NCT will conduct a trial evaluating NOXXON’s lead product candidate NOX-A12 in combination with Keytruda® in metastatic pancreatic and colorectal cancer. [NOXXON Pharma N.V.]
Press Release

Aurinia Pharmaceuticals Inc. announced that the first patient has been dosed in AURORA, the company’s Phase III confirmatory clinical trial evaluating voclosporin for the treatment of lupus nephritis, an autoimmune disease caused by lupus that involves extreme inflammation and failure of the kidneys. [Aurinia Pharmaceuticals Inc.]
Press Release

UK scientists worried about how Brexit will affect their funding received a boost when the country’s three main national parties pledged long-term targets to raise research spending. [Nature News]
Editorial

Last month, Springer, announced that the journal Tumor Biology was retracting 107 papers after finding that the peer-review process had been compromised. It was the third mass retraction at Tumor Biology. But that’s not Tumor Biology’s only problem. ScienceInsider has discovered that the journal’s editorial board, as published online, contains the names of several scientists who say they have no relationship whatsoever with the journal—including German Nobel laureate Harald zur Hausen. [ScienceInsider]
Editorial

As health officials and aid workers head to a remote corner of the Democratic Republic of the Congo to respond to an outbreak of Ebola virus disease, a key question remains: Will the government authorize the use of a promising experimental vaccine? The vaccine had stunning results in a clinical trial in Guinea in 2015, but it has yet to be licensed for broad use. [ScienceInsider]
Editorial

Lawmakers from both sides of the aisle in the U.S. House of Representatives voiced their displeasure with the Trump administration’s proposed $5.8 billion cut to the budget of the National Institutes of Health in Bethesda, Maryland. [ScienceInsider]
Editorial